Impact of newer antipsychotics on outcomes in schizophrenia

Clinical Therapeutics

Volumn 19, Issue 1, 1997, Pages 148-158

  Keks, Nicholas A ^a  

^a ALFRED HOSPITAL   (Australia)

Author keywords

cognitive function; cost of schizophrenia; pharmacoeconomic modeling; quality of life; schizophrenia

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; COST; COST BENEFIT ANALYSIS; DECISION THEORY; HUMAN; MODEL; QUALITY OF LIFE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 0030887463     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(97)80082-3     Document Type: Conference Paper

References (39)

1. Andreasen NC, Carpenter WT. Diagnosis and classification of schizophrenia. Schizophr Bull. 1993;19:199-214.
2. Carpenter WT, Buchanan RW. Schizophrenia. NEJM. 1994;330:681-690.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
4. Andreasen NC, Flaum M. Schizophrenia: The characteristic symptoms. Schizophr Bull. 1991;17:274-279.
5. Cutting J. Descriptive psychopathology. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Oxford, England: Blackwell; 1995.
6. Gold JM, Harvey PD. Cognitive deficits in schizophrenia. Psychiatr Clin North Am. 1993;i6:295-311.
7. Keks NA, Burrows GD. New medications for the schizophrenics. Med J Aust. 1994; 160:53-54.
8. Keks NA. Schizophrenia. Aust J Hosp Pharm. 1996;26:93-96.
9. Lehman AF, Thompson JW, Dixon LB, Scott JE. Schizophrenia: Treatment outcomes research - editors' introduction. Schizophr Bull. 1995;21:561-566.
10. Rupp A, Keith S. The costs of schizophrenia. Assessing the burden. Psychiatr Clin North Am. 1993;16:413-423.
11. Souetre E. Health economic considerations in the treatment of schizophrenia. Presented at the 8th Congress of the European College of Neuropsychopharmacology; September 30 to October 4, 1995; Venice, Italy.
12. Goldberg D. Cost-effectiveness studies in the treatment of schizophrenia: A review. Schizophr Bull. 1991;17:453-459.
13. Test MA, Knoedler WH, Allness DJ, et al. Long-term community care through an assertive continuous treatment team. In: Tamminga CA, Schulz SC, eds. Schizophrenia Research. New York: Raven Press; 1991:239-246.
14. Meltzer HY. Dimensions of outcome with clozapine. Br J Psychiatry. 1992;160: 46-53.
15. Meltzer HY, Cola P, Way L, et al. Costeffectiveness of clozapine in neurolepticresistant schizophrenia. Am J Psychiatry. 1993;150:1630-1638.
16. Leysen JE, Janssen PMF, Megens AA, Schott A. Risperidone: A novel antipsycholic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994;55:5-12.
17. Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebocontrolled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13:25-40.
18. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825-835.
19. Maynard A, Bloor K. Economic evaluation of mental health services. Curr Opin Psychiatry. 1995;8:122-125.
20. Davies L, Drummond M. Assessment of the costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry. 1993; 162:38-42.
21. Davies A. Efficacy, safety and cost effectiveness of risperidone versus haloperidol. I. Meta-analysis. Data on file, Janssen-Cilag, Beerse, Belgium, 1995.
22. Davies A. Efficacy, safety and cost effectiveness of risperidone versus haloperidol. II. Cost-effectiveness. Data on file, Janssen-Cilag, Beerse, Belgium, 1995.
23. Addington DE, Jones B, Bloom D, et al. Reduction of hospital days in chronic schizophrenic patients treated with risperidone: A retrospective study. Clin Ther. 1993;15:917-926.
24. Lindström E, Eriksson B, Hellgren A, et al. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia. Clin Ther. 1995;17:402-412.
25. Negron AE, Leiderman EA, Parkadavil M, et al. Naturalistic outcome of risperidone treatment in an academic state hospital setting. Presented at the seventh annual meeting of the New York Office of Mental Health; December 7-9, 1994; Albany. New York.
26. Thompson D. Cost and benefit analysis for clozapine and risperidone. Presented at the 149th annual meeting of the American Psychiatric Association; May 4-9, 1996; New York, New York.
27. Patrick D, Erickson P. Health Status and Health Policy: Allocating Resources to Health Care. New York, NY: Oxford University Press; 1993.
28. Reviaki DA, Murray M. Assessing health related quality of life outcomes of drug treatments for psychiatric disorders. CNS Drugs. 1994;1:465-476.
29. Bergner M. Quality of life, health status and clinical research. Med Care. 1989;27 (Suppl 3):S148-S156.
30. Awad AG, Hogan TP. Subjective response to neuroleptics and the quality of life: Implications for treatment outcome. Acta Psychiatr Scand. 1994;89:27-32.
31. Fogel BS. A neuropsychiatric approach to impairment of goal-directed behaviour. Presented at the 149th annual meeting of the American Psychiatric Association; May 4-9, 1996; New York, New York.
32. Goldberg TE, Gold JM. Neurocognitive deficits in schizophrenia. In: Hirsch SR, Weinberger DR, eds. Schizophrenia. Oxford, England: Blackwell; 1995:146-162.
33. Royall DR. Neuroanatomy, measurement and clinical significance of the executive cognitive functions. Presented at the 149th annual meeting of the American Psychiatric Association; May 4-9, 1996; New York, New York.
34. Weinberger DR, Berman KF, Zee RF. Physiologic significance of dorsolateral prefrontal cortex in schizophrenia. I: Regional cerebral blood flow evidence. Arch Gen Psychiatry. 1986;43:114-124.
35. Lee MA, Thompson PA, Meltzer HY. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry. 1994;55: 82-87.
36. Goldberg TE, Greenberg RD, Griffin SJ, et al. The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry. 1993;162: 43-48.
37. Goldberg TE, Daniel DG, Pickar D, et al. Differential effects of risperidone and conventional neuroleptics on neurocognition: A pilot study. Abstract.
38. Gallhofer B, Bauer U, Lis S, et al. Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol. 1996; 6(Suppl 2):S2-13-S2-20.
39. Meltzer HY, Cola P, Way L, et al. Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry. 1993;150:1630-1638.